The growing influence of a few dominant drug companies is raising significant fears globally. This phenomenon towards monopolies frequently contributes to escalated drug charges, limited innovation, and obstacles in obtaining essential medications for patients in the world. Experts suggest that e

India's pharmaceutical landscape presents a complex picture, largely shaped by the substantial influence of a few leading players. While the sector is often lauded for its generic drug manufacturing capabilities, a closer examination reveals a degree of sector concentration that warrants scrutiny